NCT05739292View on ClinicalTrials.gov

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

May 10, 2023

Study Completion Date

October 4, 2023

Conditions
Infection, Meningococcal
Interventions
BIOLOGICAL

EuNmCV-5

0.5mL single intramuscular dose on Day 0

BIOLOGICAL

Menveo

0.5mL single intramuscular dose on Day 0

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

EuBiologics Co.,Ltd

INDUSTRY

NCT05739292 - Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old | Biotech Hunter | Biotech Hunter